Amivantamab, a bispecific EGFR/MET antibody, was initially approved for NSCLC patients with exon 20 insertion mutations (Exon20ins), which are typically resistant to traditional EGFR TKIs [34,35]. The gene discussed is MET; the disease is non-small cell lung carcinoma.